Seawolf Therapeutics Raises $100 Million to Advance DNA-Based Therapeutics

Seawolf Therapeutics emerged from stealth with $100 million raised through seed and Series A financing involving Versant Ventures, MPM BioImpact, Novartis Venture Fund and other investors. The company also announced a Sanofi collaboration with up to $1.2 billion in potential milestones, plus royalties.
- Raised
- $100 million
- Round
- Seed and Series A
- Investors
- 8
- Investors
- Versant VenturesMPM BioImpactNovartis Venture FundEli Lilly and CompanyCRISPR Therapeutics AGSixty Degree CapitalAlexandria Venture InvestmentsPathway to Cures
- Target market
- Metabolic and rare diseases
- Use of funds
- Advance the portfolio of therapeutics leveraging the TRIDENT redosable lipid nanoparticle-based DNA delivery system
Get started
Create a free account to read the full story.
Quick Answers
What is the latest news about Seawolf Therapeutics?
Seawolf Therapeutics emerged from stealth with $100 million raised through seed and Series A financing involving Versant Ventures, MPM BioImpact, Novartis Venture Fund and other investors. The company also announced a Sanofi collaboration with up to $1.2 billion in potential milestones, plus royalties.
What does Seawolf Therapeutics do?
Seawolf Therapeutics is a privately held biotechnology company headquartered in San Diego, CA. It develops therapeutics using a proprietary lipid nanoparticle-based DNA delivery platform designed to enable long-term, stable expression of therapeutic proteins.
How much did Seawolf Therapeutics raise?
Seawolf Therapeutics raised $100 million in its Seed and Series A.
Who invested in Seawolf Therapeutics?
Investors named in this Seed and Series A include Versant Ventures, MPM BioImpact, Novartis Venture Fund, Eli Lilly and Company, CRISPR Therapeutics AG, Sixty Degree Capital, Alexandria Venture Investments and Pathway to Cures.
How will Seawolf Therapeutics use the funding?
Seawolf Therapeutics plans to use the money for advance the portfolio of therapeutics leveraging the TRIDENT redosable lipid nanoparticle-based DNA delivery system.
Where is Seawolf Therapeutics based?
Seawolf Therapeutics is based in USA.
Who are the key people at Seawolf Therapeutics?
Key people named in this report: Elizabeth Alcamo, PhD (President & CEO) and Tom Woiwode, PhD (Managing Director).
